Journal of pharmacokinetics and pharmacodynamics

Keyphrases

Publications

2024

David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Correction: Oral docetaxel plus encequidar - a pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics (2024)
Euibeom Shin, Yifan Yu, Robert R Bies, Murali Ramanathan
Authors' response to letter to editor. Journal of pharmacokinetics and pharmacodynamics (2024)
Hineptch Daungsupawong, Rujittika Mungmunpuntipantip
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment. Journal of pharmacokinetics and pharmacodynamics (2024)
Dan Sexton, Hoa Q Nguyen, Salomé Juethner, Haobin Luo, Zhiwei Zhang, Paul Jasper, Andy Z X Zhu
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema. Journal of pharmacokinetics and pharmacodynamics (2024)
David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics (2024)
David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics (2024)
Euibeom Shin, Yifan Yu, Robert R Bies, Murali Ramanathan
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM. Journal of pharmacokinetics and pharmacodynamics (2024)
Shufang Liu, Yingyi Li, Zhe Li, Shengjia Wu, John M Harrold, Dhaval K Shah
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins. Journal of pharmacokinetics and pharmacodynamics (2024)
Leonid Gibiansky, Chee M Ng, Ekaterina Gibiansky
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site. Journal of pharmacokinetics and pharmacodynamics (2024)
Deok Yong Yoon, Michael J Daniels, Rebecca J Willcocks, William T Triplett, Juan Francisco Morales, Glenn A Walter, William D Rooney, Krista Vandenborne, Sarah Kim, null null
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles. Journal of pharmacokinetics and pharmacodynamics (2024)
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease. Journal of pharmacokinetics and pharmacodynamics (2024)
Leonid Gibiansky, Ekaterina Gibiansky
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies. Journal of pharmacokinetics and pharmacodynamics (2024)

volume 51, number 1, 2024

Peter L Bonate
Thoughts on plagiarism and the case against Claudine Gay. Journal of pharmacokinetics and pharmacodynamics 51 (1) (2024)

volume 51, number 2, 2024

Sihem Ait-Oudhia
Fourteenth American Conference on Pharmacometrics (ACoP14) - Innovation and Diversity: Redefining Pharmacometrics. Journal of pharmacokinetics and pharmacodynamics 51 (2) (2024)
Sihem Ait-Oudhia
Fourteenth American Conference on Pharmacometrics (ACoP14) - Innovation and Diversity: Redefining Pharmacometrics. Journal of pharmacokinetics and pharmacodynamics 51 (2) (2024)
Sihem Ait-Oudhia
Fourteenth American Conference on Pharmacometrics (ACoP14) - Innovation and Diversity: Redefining Pharmacometrics. Journal of pharmacokinetics and pharmacodynamics 51 (2) (2024)

volume 51, number 3, 2024

Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Jasmine H Hughes, Janel Long-Boyle, Ron J Keizer
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Euibeom Shin, Yifan Yu, Robert R Bies, Murali Ramanathan
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, Andreas Krause
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Franziska Schaedeli Stark, Clarisse Chavanne, Michael G M Derks, Koen Jolling, Hendrik Maxime Lagraauw, Lars Lindbom, Klaas Prins, Hanna E Silber Baumann
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Elias D Clark, Sean D Lawley
How drug onset rate and duration of action affect drug forgiveness. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Hiie Soeorg, Riste Kalamees, Irja Lutsar, Tuuli Metsvaht
Subgroup identification-based model selection to improve the predictive performance of individualized dosing. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse, Andreas Krause
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Jasmine H Hughes, Janel Long-Boyle, Ron J Keizer
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Jasmine H Hughes, Janel Long-Boyle, Ron J Keizer
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Nikolaos Tsamandouras, Ruolun Qiu, Jim H Hughes, Kevin Sweeney, John P Prybylski, Christopher Banfield, Timothy Nicholas
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Monica Simeoni, Shuying Yang, Debra J Tompson, Richard Dimelow
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Franziska Schaedeli Stark, Clarisse Chavanne, Michael G M Derks, Koen Jolling, Hendrik Maxime Lagraauw, Lars Lindbom, Klaas Prins, Hanna E Silber Baumann
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Franziska Schaedeli Stark, Clarisse Chavanne, Michael G M Derks, Koen Jolling, Hendrik Maxime Lagraauw, Lars Lindbom, Klaas Prins, Hanna E Silber Baumann
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)
Franziska Schaedeli Stark, Clarisse Chavanne, Michael G M Derks, Koen Jolling, Hendrik Maxime Lagraauw, Lars Lindbom, Klaas Prins, Hanna E Silber Baumann
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations. Journal of pharmacokinetics and pharmacodynamics 51 (3) (2024)

volume 51, number 4, 2024

Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Miriam Schirru, Hamza Charef, Khalil-Elmehdi Ismaili, Frédérique Fenneteau, Didier Zugaj, Pierre-Olivier Tremblay, Fahima Nekka
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Tongtong Li, Sufeng Zhou, Lu Wang, Tangping Zhao, Jue Wang, Feng Shao
Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Alexander Janssen, Frank C Bennis, Marjon H Cnossen, Ron A A Mathôt, null null
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Alexander Janssen, Frank C Bennis, Marjon H Cnossen, Ron A A Mathôt, null null
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Alexander Janssen, Frank C Bennis, Marjon H Cnossen, Ron A A Mathôt, null null
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Leonid Gibiansky, Ekaterina Gibiansky
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Hineptch Daungsupawong, Rujittika Mungmunpuntipantip
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
Euibeom Shin, Yifan Yu, Robert R Bies, Murali Ramanathan
Authors' response to letter to editor. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)
David Wang, Chris Jackson, Noelyn Hung, Tak Hung, Rudolf Kwan, Wing-Kai Chan, Albert Qin, Natalie J Hughes-Medlicott, Paul Glue, Stephen B Duffull
Oral docetaxel plus encequidar - A pharmacokinetic model and evaluation against IV docetaxel. Journal of pharmacokinetics and pharmacodynamics 51 (4) (2024)